K-MEDI hub (Daegu-Gyeongbuk Medical Innovation Foundation, Chairman Jin-Young Yang) announced on the 29th that it has signed a Memorandum of Understanding (MOU) with Enamine to develop the K-DEL platform technology and establish a collaborative research framework for drug development.
Enamine, a world-renowned chemical supplier based in Ukraine, provides building blocks for drug development, an extensive compound library, and custom synthesis services, contributing to the pharmaceutical and biotechnology sectors.
K-MEDI hub's New Drug Development Center has launched 'K-DEL (DNA-Encoded Library, DEL)' service, a drug development library platform utilizing gene encoding technology. The center directly produces and provides libraries to various domestic pharmaceutical companies and research institutions.
Through this MOU with Enamine, the New Drug Development Center plans to accelerate the construction of a mega-scale DEL library by utilizing the diverse building blocks provided by Enamine. The center aims to support research to identify excellent candidate compounds using the constructed library.
Jin-Young Yang, Chairman of K-MEDI HUB, stated, We will do our utmost to ensure the successful advancement of the K-DEL platform by combining K-MEDI hub's library technology capabilities with Enamine's global compound supply expertise.
Iaroslava Kos, Director of Business Development at Enamine commented: We are thrilled to partner with K-MEDI HUB to advance the DEL platform in Korea. By providing access to Enamine’s vast collection of building blocks, which cover a wide chemical space, we aim to enhance the efficiency of screenings and identification of drug candidates. This collaboration is ideally suited for further hit-to-lead optimization based on Enamine’s make-on-demand compounds, revolutionizing the speed and effectiveness of drug development